Mr Matthew Ellis
Matthew is a founding member of Robey Warshaw, a leading financial advisory firm. In recent years, Matthew has worked on some of the most high profile merger and acquisitions in the UK, including AstraZeneca / Pfizer and BG / Shell, and was listed by Financial News in their “40 under 40 rising stars” list in 2014. Before that, Matthew spent a number of years at Goldman Sachs and Merrill Lynch. Matthew joined the Board of Trustees in July 2016.
Sir Robert Francis
Sir Robert Francis QC is a barrister specialising in medical law and has been a Queen’s Counsel since 1992. He has chaired several healthcare related inquiries, including the Mid-Staffordshire NHS Foundation Trust Public Inquiry. He is a non-executive director of the Care Quality Commission, President of the Patients Association, and a Patron of the Florence Nightingale Foundation. He was knighted in 2014 for services to healthcare and patients.
Mr Ameet Gill (OBE)
Ameet advises a range of businesses and investors on UK and international politics, including helping them navigate complex policy problems. He is Founder of Hanbury Strategy, a strategic advisory firm that provides political analysis, develops communications strategies and uses cutting edge data and research to understand public opinion. Prior to founding Hanbury, he was Chief Speechwriter, Director of Strategic Communications and Director of Strategy to Prime Minister David Cameron. He has been described by the Mail on Sunday as ‘the most influential figure from an ethnic minority background in British politics’.
Mr Shaun Grady
Shaun Grady is Vice-President Business Development Operations at AstraZeneca. His career background includes roles at ICI, Zeneca, and AstraZeneca in Corporate, Pharmaceuticals and US Legal departments, HR and Business Development. Shaun has worked on major projects including the AstraZeneca merger, creation of Avecia and Syngenta, acquisition of Cambridge Antibody Technology (CAT), MedImmune and Amylin, and the spin out of Albireo.
Dr. Suman Shirodkar
Dr. Suman Shirodkar, is a physician-scientist motivated by transformative science leading to significant patient benefit and commercially successful products. She has management consulting expertise, having led consulting engagements at McKinsey, and broad commercial experience in oncology, HIV and cardiovascular areas from previous roles at Pfizer and Novartis. She is now Chief Executive Officer at Cambridge Epigenetix Ltd. Suman has a Bachelor of Medicine & Bachelor of Surgery from the University of Bombay and competed a PhD in Virology at Harvard University.
Mr Timothy Bruno Schroder
Timothy Schroder is a curator and lecturer. He has spent most of his career in the museum sector in the US and the UK and has published extensively in the field of antique silver and goldsmiths’ work. He is a trustee of the Wallace Collection and was recently Prime Warden of the Goldsmiths’ Company.
Mr Richard Collier
Richard is a Fellow and the Finance Bursar of Balliol College, Oxford University. Prior to this role, he spent 23 years as an investment banker in London and New York with Kleinwort Benson, Lehman Brothers and JP Morgan, specialising in cross-border mergers and acquisitions. He trained as a lawyer, and was admitted to the bars of New York and the District of Columbia, and practised law for 5 years. He has also been a non-executive director of OXIP, an investment fund managing investments for charities, university endowments and pension funds.
Mr Geoffrey Bowman
Before joining the board of PCRC, in 2010 Geoffrey Bowman set up and is the chairman of the biennal Horizon Dinner Committee. His business life of forty years was spent in stockbroking in the city of London with L. Messel, Schroder Securities and Peel Hunt. He was diagnosed with Prostate Cancer in 2004 and is now retired.
Professor Prokar Dasgupta
Prokar is a Professor of Urology, leading academic urology at Guy's Hospital, King's College London. He has over 700 publications and a team of clinician-scientists developing novel robotics for the delivery of new immunological therapies in prostate cancer. He is credited with the "Dasgupta technique" of injecting Botulinum toxin in overactive bladders. Professor Dasgupta is the Editor-in-Chief of the BJUI. He was awarded the Golden Telescope by BAUS for a significant and lasting contribution to urology.
Mr Mark Clark
Mark is a consultant to the pharmaceutical industry. Previously, he spent 30 years in the City as an equity research analyst (most recently – until 2015- as joint head of Deutsche Bank’s highly-regarded European pharmaceutical research team). In addition to his consulting activities, Mark has volunteered for several health-related not-for-profit organisations and he is currently a Trustee of the international health NGO, Malaria Consortium.
Mrs Michele Hunter
Michele has been actively involved in the charity sector for nearly 30 years. She has been instrumental in raising over £10m for The October Club, she was Trustee of Children’s Liver Disease Foundation for 17 years and has managed high profile fundraising events for The Royal Hospital Chelsea, the Prostate Cancer Research Centre and others.
Mr Christopher Miller
Following an MA at Oxford, Christopher qualified as a chartered accountant with Coopers & Lybrand. After being an Associate Director at Hanson he joined the board of Wassall as CEO, before becoming Chairman of Melrose in 2003. Christopher is married with three children. He was diagnosed with prostate cancer in 2006.
Mr Ben Monro-Davies
Ben Monro-Davies is a TV journalist currently working for Sky News. He has 20 years’ experience of news production. He launched All Out Politics with Adam Boulton, and was part of the launch team for Sky News at Ten. He also oversaw the 2012 relaunch of Channel 4 News, and oversaw special BBC1 programmes to mark the beginning and the conclusion of the EU referendum campaign. He has worked closely with many of the broadcasting world’s leading journalists.
Mr Jonathan Badger
Jonathan has worked in fundraising roles across the charity, Arts and higher education sectors over the last 33 years – for causes as varied as mental health, breast cancer and the environment to Cambridge University, where he was part of the small team that delivered Europe’s first billion-pound campaign. He is currently working as a fundraising consultant, supporting Arts and education clients alongside serving as Chief Executive of The Little Foundation.